These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

160 related items for PubMed ID: 12821559

  • 1. Platelet-activating factor acetylhydrolase is mainly associated with electronegative low-density lipoprotein subfraction.
    Benítez S, Sánchez-Quesada JL, Ribas V, Jorba O, Blanco-Vaca F, González-Sastre F, Ordóñez-Llanos J.
    Circulation; 2003 Jul 08; 108(1):92-6. PubMed ID: 12821559
    [Abstract] [Full Text] [Related]

  • 2. Increased activity of platelet-activating factor acetylhydrolase in low-density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia.
    Karabina SA, Elisaf M, Bairaktari E, Tzallas C, Siamopoulos KC, Tselepis AD.
    Eur J Clin Invest; 1997 Jul 08; 27(7):595-602. PubMed ID: 9263748
    [Abstract] [Full Text] [Related]

  • 3. Partial purification and localization of platelet-activating factor acetylhydrolase from bovine seminal plasma.
    Hough SR, Parks JE.
    J Androl; 1997 Jul 08; 18(5):540-8. PubMed ID: 9349753
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. The inflammatory properties of electronegative low-density lipoprotein from type 1 diabetic patients are related to increased platelet-activating factor acetylhydrolase activity.
    Sánchez-Quesada JL, Benítez S, Pérez A, Wagner AM, Rigla M, Carreras G, Vila L, Camacho M, Arcelus R, Ordóñez-Llanos J.
    Diabetologia; 2005 Oct 08; 48(10):2162-9. PubMed ID: 16132957
    [Abstract] [Full Text] [Related]

  • 7. Electronegative low-density lipoprotein subfraction from type 2 diabetic subjects is proatherogenic and unrelated to glycemic control.
    Benítez S, Pérez A, Sánchez-Quesada JL, Wagner AM, Rigla M, Arcelus R, Jorba O, Ordóñez-Llanos J.
    Diabetes Metab Res Rev; 2007 Jan 08; 23(1):26-34. PubMed ID: 16634114
    [Abstract] [Full Text] [Related]

  • 8. Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins.
    Guerra R, Zhao B, Mooser V, Stafforini D, Johnston JM, Cohen JC.
    J Lipid Res; 1997 Nov 08; 38(11):2281-8. PubMed ID: 9392426
    [Abstract] [Full Text] [Related]

  • 9. All ApoB-containing lipoproteins induce monocyte chemotaxis and adhesion when minimally modified. Modulation of lipoprotein bioactivity by platelet-activating factor acetylhydrolase.
    Lee C, Sigari F, Segrado T, Hörkkö S, Hama S, Subbaiah PV, Miwa M, Navab M, Witztum JL, Reaven PD.
    Arterioscler Thromb Vasc Biol; 1999 Jun 08; 19(6):1437-46. PubMed ID: 10364074
    [Abstract] [Full Text] [Related]

  • 10. PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro.
    Karabina SA, Elisaf MC, Goudevenos J, Siamopoulos KC, Sideris D, Tselepis AD.
    Atherosclerosis; 1996 Aug 23; 125(1):121-34. PubMed ID: 8831934
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. PAF-acetylhydrolase, predominantly present in LDL in healthy subjects, is associated with HDL in a patient with LDL deficiency.
    Surya II, Mommersteeg M, Erkelens DW, Akkerman JW.
    J Lipid Mediat; 1991 Aug 23; 3(1):27-38. PubMed ID: 1768838
    [Abstract] [Full Text] [Related]

  • 13. Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB.
    Tsimihodimos V, Karabina SA, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, Elisaf M, Tselepis AD.
    Arterioscler Thromb Vasc Biol; 2002 Feb 01; 22(2):306-11. PubMed ID: 11834533
    [Abstract] [Full Text] [Related]

  • 14. Association of the inflammatory state in active juvenile rheumatoid arthritis with hypo-high-density lipoproteinemia and reduced lipoprotein-associated platelet-activating factor acetylhydrolase activity.
    Tselepis AD, Elisaf M, Besis S, Karabina SA, Chapman MJ, Siamopoulou A.
    Arthritis Rheum; 1999 Feb 01; 42(2):373-83. PubMed ID: 10025933
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Platelet-activating factor acetylhydrolase and transacetylase activities in human plasma low-density lipoprotein.
    Tsoukatos DC, Liapikos TA, Tselepis AD, Chapman MJ, Ninio E.
    Biochem J; 2001 Jul 15; 357(Pt 2):457-64. PubMed ID: 11439095
    [Abstract] [Full Text] [Related]

  • 17. Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma.
    Stafforini DM, Carter ME, Zimmerman GA, McIntyre TM, Prescott SM.
    Proc Natl Acad Sci U S A; 1989 Apr 15; 86(7):2393-7. PubMed ID: 2928339
    [Abstract] [Full Text] [Related]

  • 18. Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesterolemic Sicilian individuals.
    Campo S, Sardo MA, Bitto A, Bonaiuto A, Trimarchi G, Bonaiuto M, Castaldo M, Saitta C, Cristadoro S, Saitta A.
    Clin Chem; 2004 Nov 15; 50(11):2077-82. PubMed ID: 15364890
    [Abstract] [Full Text] [Related]

  • 19. Plasma and Lp(a)-associated PAF-acetylhydrolase activity in uremic patients undergoing different dialysis procedures.
    Milionis HJ, Elisaf MS, Karabina SA, Bairaktari E, Tselepis AD, Siamopoulos KC.
    Kidney Int; 1999 Dec 15; 56(6):2276-85. PubMed ID: 10594806
    [Abstract] [Full Text] [Related]

  • 20. Higher Levels of Oxidized Low Density Lipoproteins in Alzheimer's Disease Patients: Roles for Platelet Activating Factor Acetyl Hydrolase and Paraoxonase-1.
    Bacchetti T, Vignini A, Giulietti A, Nanetti L, Provinciali L, Luzzi S, Mazzanti L, Ferretti G.
    J Alzheimers Dis; 2015 Dec 15; 46(1):179-86. PubMed ID: 25720407
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.